Skip to content
MedsAcross

Medicine

Risperidone 4 mg orally disintegrating tablet

Risperidone · Oral
Available on requestPrescription onlyUS FDAGeneric name

Risperidone 4 mg orally disintegrating tablet is a generic prescription medicine for oral use, made by 5 labelers, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.

Availability

Available on request

Export supply from India to licensed buyers

Typical lead time

On request

Counted from payment and complete documents

Shipping

Ambient

Risperidone Orally Disintegrating Tablets, USP should be stored at 20° to 25°C…

Key facts

Active ingredient (INN)
Risperidone
Brand
Sold under the generic name
Strength
4 mg
Dosage form
Orally disintegrating tablet
Route
Oral
Packs
7 blister pack, 500 tablets, 1 pouch and 5 more
Manufacturers
Sun Pharmaceutical IndustriesIndiaJubilant Cadista PharmaceuticalsIndiaAmerisynAmici PharmaPar Health
Origin register
US FDA, United States
Storage
Risperidone Orally Disintegrating Tablets, USP should be stored at 20° to 25°C (68° to 77°F). Protect from light and moisture.
Cold chain
Not required on record
Prescription status
Prescription only
Controlled substance
Not recorded as controlled
ATC code
N05AX08 Risperidone
HS code (indicative)
3004.90Indicative only. Your customs broker confirms the final tariff code.
Marketing category
marketed
Marketed since
10 June 2009
Identifiers
RxCUI 401953, 401954, 403825 +3DailyMed set ID d0ef6df3-67e5-47b1-bcf7-f67aa030caca, ca41c144-224a-4d57-88d7-8778e6c69ed2, 58b7504f-c4a3-ef1b-e063-6394a90ac0f3 +2NDC 49884-403, 69292-575, 87564-017 +2Application ANDA077494, ANDA077328, ANDA090839 +1

Record updated 12 November 2026

Documents available

Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.

No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.

Packs

Packs from every labeler of this generic presentation.

PackCodeLabelerMarketed since
7 blister pack in 1 carton / 4 tablet, orally disintegrating in 1 blister pack59746-050-22Jubilant Cadista PharmacuticalsIndia4 November 2011
500 tablet, orally disintegrating in 1 bottle63304-644-05Sun Pharmaceutical IndustriesIndia6 August 2010
1 pouch in 1 box, unit-dose / 1 tablet, orally disintegrating in 1 pouch63304-644-17Sun Pharmaceutical IndustriesIndia6 August 2010
30 tablet, orally disintegrating in 1 bottle63304-644-30Sun Pharmaceutical IndustriesIndia6 August 2010
1 blister pack in 1 carton / 10 tablet, orally disintegrating in 1 blister pack63304-644-69Sun Pharmaceutical IndustriesIndia6 August 2010
4 tablet, orally disintegrating in 1 blister pack87564-017-28Amerisyn6 August 2026
7 blister pack in 1 carton / 4 tablet, orally disintegrating in 1 blister pack69292-575-28Amici Pharma1 April 2026
7 blister pack in 1 carton / 4 tablet, orally disintegrating in 1 blister pack49884-403-91Par Health10 June 2009

Status by register

Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.

RegisterStatusSource
US FDAListed, marketedSource record for this pageChecked 12 November 2026
US FDAFirst approved 29 December 1993Drugs@FDA
EU (EMA)AuthorisedEMA medicines data
India (CDSCO)Not yet confirmed against CDSCO approval lists—
AustriaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
BelgiumRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
BulgariaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
CroatiaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
CyprusRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
CzechiaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
DenmarkRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
EstoniaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
FinlandRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
FranceRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
GermanyRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
GreeceRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
HungaryRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
IcelandRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
IrelandRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
ItalyRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
LatviaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
LiechtensteinRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
LithuaniaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
LuxembourgRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
MaltaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
NetherlandsRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
NorwayRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
PolandRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
PortugalRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
RomaniaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
SlovakiaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
SloveniaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
SpainRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
SwedenRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
United StatesRegisteredUS FDA (NDC directory, openFDA)Checked 12 November 2026

Import route

Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.

Import guides are available for 25 countries. Pick one to see its route summary.

BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides

Alternatives

Other makers and brands of Risperidone 4 mg orally disintegrating tablet.

Compare 1

Other strengths and forms of Risperidone

Clinical summary

Risperidone is an atypical antipsychotic indicated for treatment of schizophrenia, among other approved uses. It is available as tablets, orally disintegrating tablets and oral solution for subcutaneous use. MedsAcross supplies Risperidone for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.

Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review

Read about Risperidone

For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.

Data sources

Need Risperidone 4 mg orally disintegrating tablet for your hospital or patient?

Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.